Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ip Group Plc LSE:IPO London Ordinary Share GB00B128J450 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.40 -2.91% 113.60 114.40 115.00 120.20 113.60 119.80 4,906,730 16:35:22
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 0.0 186.1 17.5 6.5 1,207

Ip Share Discussion Threads

Showing 2126 to 2150 of 2550 messages
Chat Pages: Latest  90  89  88  87  86  85  84  83  82  81  80  79  Older
DateSubjectAuthorDiscuss
04/2/2021
09:29
Edison Research has published an interesting report on Draper Esprit(GROW). At end of report (pages 19-21) there is a comparison of GROW with its quoted peer group which includes IPO. hxxps://www.edisongroup.com/wp-content/uploads/2021/02/Draper-Esprit-Europes-leading-pureplay-listed-VC.pdf On basis of this report IPO still looks undervalued. As a holder of HG Capital and Oakley Capital, as well as IPO, the key difference seems to be management.
bottomfisher
03/2/2021
14:12
Shareholder base is international already so no reason a SPAC deal would be blocked
robertspc1
03/2/2021
14:11
ONT can easily list or do a SPAC deal in current markets. IPO can keep all its shares as doesn't need cash, but at least this would demonstrate the hidden value in the portfolio.
robertspc1
01/2/2021
14:56
Pierre, If, as Gordon Sanghera has said, ONT are to grow tenfold over the next five years, the 15% IPGroup hold will increase in value to a far greater extent than £200m cash taken now. IPO have enough cash! The worst thing they could do is list the company before it is ready. Just look, for example, what happened to CWR, and many of the other listed constituents that were floated before they were ready.
bamboo2
01/2/2021
11:38
Nano needs to be moneytised sooner rather than later, one way or the other. Ipo probably doesn't have a great deal of say on that though. Would be great to hear ipo's plans for the cash if they suddenly find themselves with a couple more hundreds of mill cash from nano Big senior staff bonuss no doubt. That'll be all going from past experience.
pierre oreilly
31/1/2021
21:50
No, won't be allowed.
p1nkfish
31/1/2021
21:24
Ok here's a theory. A US SPAC will buy Oxford Nanopore soon. You heard it here first
robertspc1
30/1/2021
08:33
SHEIN INAUGURATES FRANCETV PUBLICITÉ’S 100% DIGITAL MIRRIAD PRODUCT PLACEMENT SOLUTION IN SKAM January 29, 2021 SKAM is a Norwegian series created in 2015, and since then adapted for France, Italy, Germany and Spain. It follows the daily lives of several high school students, with each season tackling a different problem typical of those tricky teenage years. Its advertiser, SHEIN, international online clothing platform for millennials, has chosen to use the new-generation product placement solution developed by British start-up Mirriad throughout Season 7. Mirriad has developed an augmented reality process that allows SHEIN to integrate its brand into the various episodes of SKAM during post-production naturally, consistently and in a flattering environment. The brand will appear for example in the form of a poster in outdoor scenes and on shopping bags in indoor scenes. Https://www.francetvpub.fr/en/shein-inaugurates-francetv-publicites-100-digital-mirriad-product-placement-solution-in-skam/
bamboo2
30/1/2021
08:33
If we were to see a return to similar average daily volumes before forced selling started [Pre-Woodford] daily average would drop below 1m shares. Approx 70m shares traded in January over 20 trading days.* * = The 70m shares total for January excludes the large block trade of 7% of the company traded by Invesco in the rns on the 11/1/2021 7% is an additional 75m shares.
bamboo2
28/1/2021
20:45
As well as detecting SARS-CoV-2, LamPORE is in development for the detection of other respiratory viruses at the same time, including flu and respiratory syncytial virus (RSV). ========================================= Dr Gordon Sanghera, CEO of Oxford Nanopore, said: This remarkable study is a testament to the scientific teams who worked so hard over the summer to validate a new generation of diagnostic test. We believe there are phenomenal opportunities here: not only to deliver high quality COVID testing, but to catalyse the development and delivery of real-time, data-rich clinical testing using nanopore sequencing. This has the potential to tackle infectious disease and to reach into cancer, rare disease, and tissue typing/immunology.
bamboo2
28/1/2021
18:45
Https://www.gov.uk/government/news/clinical-evaluation-confirms-high-accuracy-of-highly-mobile-lampore-test Press release Clinical evaluation confirms high accuracy of highly mobile LamPORE test Findings from large-scale technical and clinical evaluation of LamPORE COVID-19 test confirm high sensitivity and specificity. Published 28 January 2021 From: Department of Health and Social Care Evaluation carried out by NHS trusts and universities finds test to be highly effective in detecting the virus in people with and without symptoms LamPORE technology is highly mobile, with pop-up laboratories being piloted in Aberdeen, Telford, Brent and Newbury A technical and clinical evaluation conducted by NHS trusts and universities has confirmed the LamPORE COVID-19 test, produced by Oxford Nanopore, to be accurate and sensitive enough to detect the virus in people with and without symptoms. LamPORE test technology is a highly mobile and scalable solution – it can be operated in traditional laboratory settings, as well as smaller spaces. This means the technology can be quickly deployed to areas to provide additional testing capacity where it is needed for large numbers of people, alongside existing PCR testing capacity and community testing using lateral flow tests. LamPORE uses swab samples in the same way as a traditional PCR test, but also shows high performance with saliva samples. The LamPORE test was assessed on saliva and swab samples from symptomatic and asymptomatic participants. With samples from asymptomatic participants, the LamPORE test was found to have an overall sensitivity of 99.57% and specificity of 99.4%, meaning the test is highly effective for testing people without symptoms in the community. As well as detecting SARS-CoV-2, LamPORE is in development for the detection of other respiratory viruses at the same time, including flu and respiratory syncytial virus (RSV). LamPORE technology is currently being piloted for use in mobile laboratories. In these pilots, pop-up laboratories which can process tests on-site using LamPORE technology have been set up in trucks which can travel to areas where there is a need for testing, processing up to 2,000 tests a day. There are currently 4 mobile LamPORE units, deployed in Aberdeen, Telford, Brent and Newbury, being piloted to provide local testing services. This week, the first LamPORE mobile laboratory to arrive in Scotland started testing in Aberdeen, where it will move around to provide testing for those in remote locations. Pilots will continue into next month, followed by an evaluation of the mobile units. LamPORE technology combines loop-mediated isothermal amplification (LAMP) and nanopore sequencing to provide highly scalable detection of COVID-19. The test is CE marked for usage with the Oxford Nanopore GridION device, which can process thousands of tests a day. Health Minister Lord Bethell said: With one in three people not displaying symptoms of COVID-19, broadening asymptomatic testing is critical to protect those at highest risk. Oxford Nanopore’s LamPORE test is another example of British innovation leading the way, and is an incredibly useful addition to our COVID-19 testing toolkit – delivering accurate results to people with and without symptoms. The LamPORE mobile laboratories provide a new way in which we can respond to testing demand where there is most need. I am hugely grateful to Oxford Nanopore for their efforts in producing this technology. Professor Dame Sue Hill, Chief Scientific Officer for England in NHS Test and Trace, who led the evaluation of Oxford Nanopore LamPORE test, said: The LamPORE test shows very high sensitivity, so can be used for the full range of diagnostic and other use cases. This study showed it to be effective when using saliva samples from people without symptoms and it has the additional advantage of being able to detect other winter viruses, such as flu, increasing the scenarios in which it could be deployed. Minister for Public Health Mairi Gougeon said: I welcome the arrival of this unit, which will significantly decrease turnaround times for people being tested at mobile testing units (MTUs) and drive-through testing centres in the north east. This follows the expansion of our community testing programme through the national MTU fleet, which is operated by the Scottish Ambulance Service. In partnership with the UK government, and through additional funding of £800,000 from the Scottish government, this fleet will grow from 18 to 42 by March 2021, with capacity to reach 84 communities. We will continue to work with the UK government and local partners to improve access to COVID testing. However, it’s important to remember testing is only one layer of protection – all others, including vaccination and the FACTS guidance work to greatest effect when they work together, so it is essential people continue to follow the restrictions currently in place to suppress COVID to the lowest possible level in Scotland. Dr Gordon Sanghera, CEO of Oxford Nanopore, said: This remarkable study is a testament to the scientific teams who worked so hard over the summer to validate a new generation of diagnostic test. We believe there are phenomenal opportunities here: not only to deliver high quality COVID testing, but to catalyse the development and delivery of real-time, data-rich clinical testing using nanopore sequencing. This has the potential to tackle infectious disease and to reach into cancer, rare disease, and tissue typing/immunology. Background information Read the full LamPORE evaluation report. Https://www.gov.uk/government/publications/rapid-evaluation-of-oxford-nanopore-technologies-lampore-assay A brief summary of key findings from the pilot studies: on swab samples from symptomatic patients, the LamPORE assay with RNA extraction returned a sensitivity of 100% and a specificity of 100% on swab samples from asymptomatic patients, the LamPORE assay with RNA extraction returned a sensitivity of 99.6% and specificity of 99.4% on saliva samples from asymptomatic patients, the LamPORE assay with RNA extraction returned a sensitivity of 98.9% and specificity of 99.4% The Technical and Validation Group was established under NHS Test and Trace, inclusive of NHS and PHE experts and working closely with MHRA and research bodies. The technical and validation function considers manufacturers of SARS-CoV-2 (COVID-19) tests for viral detection and registers their interest in the national procurement process if their test meets, or are intended to meet the requirements of the relevant Medicines and Healthcare Products Regulatory Agency (MHRA) target product profiles. The asymptomatic pilot study recruited 1,200 healthcare workers across 4 hospital sites: University Hospitals Birmingham NHS Foundation Trust University Hospitals Southampton NHS Foundation Trust Hampshire Hospitals NHS Foundation Trust Manchester Hospitals NHS Foundation Trust A total of 3,966 swab and 18,435 saliva samples were collected as part of this study.
bamboo2
28/1/2021
18:34
Covid-19: No-swab saliva test finds symptomless cases By Michelle Roberts Health editor, BBC News online 46 minutes ago Https://www.bbc.co.uk/news/health-55840547 People may soon be offered a "spit in a pot" coronavirus test, after promising trial results. The LampORE test checks for the virus in saliva samples, and work carried out with the help of more than 1,000 NHS volunteers shows it is good at finding cases, even if someone has no symptoms. Pop-up labs that can process up to 2,000 tests a day have been set up in trucks that could travel the country. Four have already been deployed, says the government. These mobile units are located in Aberdeen, Telford, Brent and Newbury. They will continue testing people in the coming weeks and the results will be evaluated to see how helpful the service is. In the trials done so far, the LamPORE Covid-19 test, produced by Oxford Nanopore, was accurate and sensitive enough to identify people - in this instance, NHS staff - who were infected, with or without symptoms. As well as detecting coronavirus, it could be used at the same time to spot other respiratory viruses, such as flu. The test also has the advantage of not needing a swab up the nose or down the throat, which some people find uncomfortable. The "gold standard" test for checking for coronavirus is still the one used by the Test and Trace service - a check called PCR, which does require a swab. How does mass testing work? If you think you might have coronavirus, you should get checked. In the UK, you can order a test online at gov.uk or call 119. Health Minister Lord Bethell said: "With one in three people not displaying symptoms of Covid-19, broadening asymptomatic testing is critical to protect those at highest risk. "The LamPORE mobile laboratories provide a new way in which we can respond to testing demand where there is most need."
bamboo2
27/1/2021
08:18
Yesterday's potential turn looks like it will confirm today. Complete guess, but looking at recent volume, and likely overhangs at both Invesco and Lansdowne, think it's possible we will see the end of forced sellers later this week. RSI suggests stock is now oversold. gla
bamboo2
26/1/2021
19:52
Good idea Wetz. All I can see is that pool of data growing. It's potential usefulness is massive and value could far outweigh any hardware value used to collect the data.
p1nkfish
26/1/2021
18:45
P1nk, you’re right about the value that exists in offering a comprehensive genetic data analysis service. The market is vast, but I think the breadth of information is too broad for it to be captured by one provider. Much of the information is in the public domain and the scope is vast. ONT do have a fledgling data service but I think the most realistic future for this is to act as a platform where clients can access curated databases from specialist providers, e.g. for horticulture, human pathogens, forensics etc.
wetpantz
26/1/2021
18:30
Hmmm, interesting that Sanghera chose to be interviewed by Barron’s, suggests he is mulling a NASDAQ listing. If Cathy Woods picks up some ONT for her ARK genomics fund the share price will likely go stratospheric.
wetpantz
26/1/2021
16:37
my guess is if they are not finished buying they have a certain grace period before disclosure or the sale was to multiple parties who are not subject to disclosure as they individually are less than 3% rule. i might be wrong ...
edwardt
26/1/2021
10:52
Benchmark, re 762 29/12/2020 price gapped up at the open. This gap showed on the mid price based chart, but not on the last market price based chart. It was filled yesterday. Onwards and upwards.
bamboo2
26/1/2021
09:35
Bottomfisher, It's not just the recent 7%. I can't account for who is holding approx 25% of the company [That is, of the approx 45% sold by forced sellers in the past 12 months]. The only explanation of this situation is that IPO shares are being accumulated in the background. The update to 31/12/2020 should detail the position of significant holders.
bamboo2
26/1/2021
09:26
Ipo need to go through the register and sort it out.
p1nkfish
26/1/2021
09:22
I find it disappointing that more than two weeks after Invesco sold a 7% stake in IPO there is still no idea of where the shares have gone to which perhaps explains the recent weakness of the share price. If IPO is so undervalued why is it not attracting the interest of serious institutional investors?
bottomfisher
26/1/2021
08:12
eeza, Price also now into historical support zone and starting to look oversold. Potential turn on my chart for today. I hope we will soon see the end of the forced sellers.
bamboo2
25/1/2021
22:21
SP now touching the 50sma.
eeza
25/1/2021
21:20
Oxford Nanopore’s Gene-Sequencing Is Helping the Global Battle Against Covid. It’s Now Considering an IPO. By Lina Saigol Updated Jan. 25, 2021 3:55 pm ET / Original Jan. 25, 2021 5:24 am ET Https://www.barrons.com/articles/how-oxford-nanopores-gene-sequencing-is-helping-the-global-battle-against-covid-its-now-considering-an-ipo-51611570281 Fifteen years ago, Gordon Sanghera set out to disrupt the scientific research market by building a new science-based company that could revolutionize DNA sequencing by providing a fast, cheap way of providing real-time surveillance. Now the chief executive of Oxford Nanopore Technologies finds himself at the center of the fight against the Covid-19 pandemic and is also considering his options, including an initial public offering, for the future for the company. Oxford Nanopore has been thrown into the spotlight as countries across the world race to track the emergence of new variants of the coronavirus that causes Covid-19, such as those identified in the U.K., Brazil and South Africa. These are driving an alarming spike in cases and have the potential to reduce or even eliminate the efficacy of the vaccines. Scientists are increasingly turning to Oxford Nanopore’s hand-held DNA sequencing device called MinION. The size of a cellphone, and weighing less than four ounces, the device runs off a laptop USB plug and costs just $1,000, making it simpler, cheaper and faster to sequence without the need for big clinical laboratories. “Our goal has been to democratize access to DNA sequencing and provide universal access to real-time genomic surveillance,” Sanghera said in an interview with Barron’s. “There is no more urgent need to do this as there is now.” This isn’t unlike another important U.K export: the Covid-19 vaccine developed by U.K.-Swedish drug company AstraZeneca with the University of Oxford, which is low cost and can be safely stored and transported at standard refrigerator temperatures, making it easier to distribute. By comparison, the shot developed by U.S. drug company Pfizer with its German partner BioNTech requires storage at minus 70C. Since the outbreak of the pandemic last January, Oxford Nanopore’s sequencing technology has been used to support scientists in more than 50 countries, including China, and more recently Brazil, as they sequence the virus to track its transmission and evolution. “Information is everything in the pandemic,” Sanghera said, explaining that scientists have traditionally had to collect hundreds of samples and wait for weeks for the results. “You can buy the device on a Monday, have it shipped by Tuesday, genome sequence on Wednesday and sample the data on Thursday,” he said. The company’s evolution has been reflected in its investor base, as it has dialed down its reliance on London-based investors and now counts Singapore’s sovereign-wealth fund GIC and China Construction Bank International among its investors. In October, Abu Dhabi-listed International Holdings Company invested £39 million in Oxford Nanopore as part of a £84.4 million equity raise, taking the firm’s total funding to £613 million ($840.2 million) since founding. That gives it a valuation of £1.5 billion ($2 billion)—making it one of the U.K.’s rare “unicorns”—an unlisted technology company valued at more than $1 billion. It would be a prime candidate for an IPO, which is something Sanghera is now considering alongside other options with his advisors. Meanwhile, the company plans to use the cash from its latest funding round to ramp up its commercial and manufacturing operations so it can distribute its products internationally, as well as boosting its rapid Covid-19 testing capability. The company teamed up with the U.K. government last year to provide its LamPORE Covid test—developed from scratch in six months—which can determine whether a user has coronavirus in under an hour. The test is currently being rolled out in mobile testing units across the U.K. But Sanghera’s ambitions go beyond the Covid-19 pandemic, with hopes that its devices could be used in the future to identify common infections and prevent the overuse of antibiotics and other prescription drugs. Surgeons in Tel Aviv recently used the device when removing a tumor from the abdominal cavity of a patient, to make sure they had extracted all the cancer cells. In Canada, it is helping to more precisely match organ donors to patients, which Sanghera said can be done in the space of three to five hours. Oxford Nanopore has also has developed a larger, very high throughput device, the PromethION, which now has the potential to sequence up to 150 human genomes on a desktop device. Pitted against large instruments from other providers like Illumina, the data format that Nanopore offers provides richer data, which Sanghera describes as “like watching color television instead of black and white.” “If nothing else happens with this company, as long as we save some lives, I’ll be happy,” Sanghera said.
bamboo2
25/1/2021
16:39
Wet, do ONT have any chance to data mine the info? Forget owning it per se but ability to deep dive to look for links and commonalities? Their target was to sequence the world. All well and good but the real value is in the data delivered from the sequencing. Worth many, many billions in the right hands.
p1nkfish
Chat Pages: Latest  90  89  88  87  86  85  84  83  82  81  80  79  Older
ADVFN Advertorial
Your Recent History
LSE
IPO
Ip
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210621 05:23:16